Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study
Year: 2026
Type: article
Study design: Observational Study
Abstract: ABSTRACT: Bispecific antibodies (BsAb) targeting CD20 and CD3 have shown efficacy for relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), but their impact on outcomes following allogeneic hematopoietic cell transplantation (alloHCT) remains unclear. In this international, retrospective study, we compared outcomes of adult patients with R/R B-NHL undergoing first alloHCT after BsAb exposure (n = 47) versus a historical BsAb-naïve cohort (n = 101). Baseline imbalances were addressed using inverse probability of treatment weighting (IPTW) and propensity score matching (PSM). The primary end point was nonrelapse mortality (NRM); secondary end points included overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), graft-versus-host disease (GVHD), engraftment, and GVHD/relapse-free survival (GRFS). In the overall cohort, 2-year NRM did not differ significantly between BsAb-exposed and BsAb-naïve groups (IPTW: 29.1% vs 31.4%, P = 0.80; PSM: 35.8% vs. 27.9%, P = 0.43). CIR was significantly lower in BsAb-exposed patients after IPTW (7.4% vs 20.0%, P = 0.01), but not in PSM (9.5% vs 23.4%, P = 0.06). OS, GVHD, GRFS, and engraftment were comparable. In a prespecified subanalysis limited to large B-cell lymphomas, CIR differences were consistent across IPTW (6.1% vs 21.1%, P = 0.01) and PSM (9.2% vs 33.3%, P = 0.03), reinforcing a potential benefit of prior BsAb therapy. A significant improvement in PFS was observed in this subgroup with IPTW (55.5% vs 36.6%; P = 0.04), but not in PSM (P = 0.20). Prior BsAb exposure does not adversely impact alloHCT safety and may be associated with improved disease control. Prospective studies are warranted to define optimal sequencing in this high-risk population.
Source: Blood Advances
Authors: Marta Peña, Giulia Losi, Víctor Navarro, David A. Qualls, Jennifer L. Crombie, Jacopo Mariotti, Stefania Bramanti, Nicole Fabbri, Ángel Serna, Yasmina I. M. Serroukh, Aitana Balaguer-Rosselló, Marjolein W. M. Van Der Poel, Ya-Ting Hsu, Ana Jiménez-Ubieto, Christopher McKinnely, Lucía López-Corral, Carlos Panizo, José Antonio Pérez-Simón, Montserrat Rovira, Raquel Saldaña, Mi Kwon, Carlos Solano, David Valcárcel, María Jesús Pascual-Cascón, Víctor Noriega, Jaime Sanz, Andrés Sánchez-Salinas, Manuel Jurado, Maria Calbacho, Leyre Bento, Carmen Albo López, Maria Perera, Inmaculada Heras, Manuel Guerreiro, Pascual Balsalobre, Philippe Armand, Anna Sureda, Alberto Mussetti
Institutions: Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Universitat de Barcelona, Policlinico San Matteo Fondazione, Vall d'Hebron Institute of Oncology, Dana-Farber Cancer Institute, Istituto di Ematologia di Bologna, University of Bologna, Vall d'Hebron Hospital Universitari, Erasmus MC, Erasmus MC Cancer Institute, Hospital Universitari i Politècnic La Fe, Maastricht University Medical Centre, Maastricht University, National Cheng Kung University Hospital, National Cheng Kung University, Hospital Universitario 12 De Octubre, Fiona Stanley Hospital, Fiona Stanley Fremantle Hospitals Group, Instituto de Investigación Biomédica de Salamanca, Donostiako Unibertsitate Ospitalea, Consejo Superior de Investigaciones Científicas, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Hospital Clínic de Barcelona, Hospital Universitario de Jerez, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital Clínico Universitario de Valencia, Hospital Regional Universitario de Málaga, Complexo Hospitalario Universitario A Coruña, Hospital Universitario Virgen de la Arrixaca, Hospital Universitario Virgen de las Nieves, Health Research Institute of the Balearic Islands, Hospital Universitario Son Espases, University Hospital Complex Of Vigo, Hospital Universitario de Gran Canaria Doctor Negrín, Hospital General Universitario Morales Meseguer, IPO Porto, Grupo Español de Trasplante Hematopoyético y Terapia Celular
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,800
OpenAlex ID: W7123515064